Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Christopher Cabell is President & Head of R&D at Inhibikase Therapeutics. OQRO lists 2 transactions filed with the SEC under this name, the latest on Feb 25, 2026, each linked to the official Form 4.
President & Head of R&D
Disclosures on record
2
Companies involved
1
Inhibikase TherapeuticsIKT
2 disclosures · Jan 2026 – Feb 2026
Feb 21, 2026338Kdisclosed Feb 25
DetailsOfficial recordJan 5, 2026900Kdisclosed Jan 7
DetailsOfficial recordAs of the latest filing on , Christopher Cabell reported holding 676,564 shares of Inhibikase Therapeutics (IKT), worth about $880K at the last close of $1 (Nov 19, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Inhibikase Therapeutics IKT | 676,564 | 677K direct | $1 | $880K | Feb 21, 2026 |
Is this Christopher Cabell’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Feb 21, 2026, Christopher Cabell reported holding 676,564 shares of Inhibikase Therapeutics (IKT). At the last close of $1 on Nov 19, 2026, that is about $880K. This is the stake disclosed in filings, not a net worth.
No public filing gives Christopher Cabell's net worth. What SEC Form 4 shows is the stock stake: 676,564 shares of Inhibikase Therapeutics (IKT), about $880K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.